Graphical abstract describing design of “Y”-shaped symmetric 2C inhibitors. See link to paper below.
Invention Summary:
The genus Enterovirus of Picornaviridae contains many significant pathogens related to human and mammalian diseases. Enterovirus D68 (EV-D68) infection is linked to the neurological disorder acute flaccid myelitis (AFM), where both infections and incidence of AFM have been consistently increasing for the past decade. Recent efforts in EV disease research have identified compounds with limited efficacy in the inhibition of EV-D68. However, additional and specific antivirals are needed to combat EV-D68, as these inhibitors demonstrate a lack of potency and selectivity, as well as pharmacokinetic property liabilities, which impedes development into clinical candidates.
Researchers at Rutgers have designed and tested telaprevir-derived inhibitors that target the 2C protein of EV-D68 and demonstrate high potency. Supported by fluorescence polarization data, published results demonstrate effective inhibition of viral replication.
Market Applications:
Therapeutic Development for Enteroviruses
Pandemic Preparedness and Response
Advantages:
Validated lead compounds derived from virtual screening
Demonstrated nanomolar inhibition potency
Publications:
• J. Med. Chem. 2025, 68, 13, 14041–14053
Intellectual Property & Development Status: Provisional application filed. Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships, contact: marketingbd@research.rutgers.edu